Effectiveness and cost-effectiveness of blood pressure screening in adolescents in the United States

J Pediatr. 2011 Feb;158(2):257-64.e1-7. doi: 10.1016/j.jpeds.2010.07.058. Epub 2010 Sep 17.

Abstract

Objective: To compare the long-term effectiveness and cost-effectiveness of 3 approaches to managing elevated blood pressure (BP) in adolescents in the United States: no intervention, "screen-and-treat," and population-wide strategies to lower the entire BP distribution.

Study design: We used a simulation model to combine several data sources to project the lifetime costs and cardiovascular outcomes for a cohort of 15-year-old U.S. adolescents under different BP approaches and conducted cost-effectiveness analysis. We obtained BP distributions from the National Health and Nutrition Examination Survey 1999-2004 and used childhood-to-adult longitudinal correlation analyses to simulate the tracking of BP. We then used the coronary heart disease policy model to estimate lifetime coronary heart disease events, costs, and quality-adjusted life years (QALY).

Results: Among screen-and-treat strategies, finding and treating the adolescents at highest risk (eg, left ventricular hypertrophy) was most cost-effective ($18000/QALY [boys] and $47000/QALY [girls]). However, all screen-and-treat strategies were dominated by population-wide strategies such as salt reduction (cost-saving [boys] and $650/QALY [girls]) and increasing physical education ($11000/QALY [boys] and $35000/QALY [girls]).

Conclusions: Routine adolescents BP screening is moderately effective, but population-based BP interventions with broader reach could potentially be less costly and more effective for early cardiovascular disease prevention and should be implemented in parallel.

Publication types

  • Comparative Study
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adolescent
  • Antihypertensive Agents / adverse effects
  • Antihypertensive Agents / therapeutic use
  • Blood Pressure Determination
  • Cohort Studies
  • Coronary Disease / economics
  • Coronary Disease / prevention & control*
  • Cost Savings*
  • Cost-Benefit Analysis
  • Female
  • Humans
  • Hypertension / drug therapy
  • Hypertension / economics*
  • Hypertension / epidemiology*
  • Male
  • Markov Chains
  • Mass Screening / economics*
  • Mass Screening / methods
  • Program Evaluation
  • Quality-Adjusted Life Years
  • Risk Assessment
  • United States

Substances

  • Antihypertensive Agents